www.fdanews.com/articles/207967-fda-greenlights-dermavants-vtama-cream-for-psoriasis
FDA Greenlights Dermavant’s Vtama Cream for Psoriasis
May 25, 2022
The FDA has approved Dermavant’s Vtama (tapinarof) cream, 1 percent, as a topical treatment for patients with plaque psoriasis.
An aryl hydrocarbon receptor agonist, Vtama is the first steroid-free topical medication in its class that has been FDA-approved. The drug is indicated for all levels of disease severity in plaque psoriasis patients and for an unlimited duration of use.
The agency approval was supported by positive data from two late-stage trials in which Vtama demonstrated statistically significant improvements in skin clearance and in Psoriasis Area and Severity Index scores.
Dermavant, a Roivant Sciences subsidiary, said it plans to launch the product on the U.S. in June.